For Healthcare Professionals

ATRi Transition Rollover Study

clipboard-pencil

About the study

The main purpose of the study is to monitor the safety of participant receiving long-term treatment of M6620 as monotherapy or in combination with carboplatin and paclitaxel.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Participants ongoing treatment in Vertex study VX13-970-002.
  2. Participant must be able to understand and provide written informed consent.
  3. Participant must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.

EXCLUSION CRITERIA

  1. Participants experiencing disease progression or unacceptable toxicity at the time of transition into the this study.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +49 6151 72 5200Email iconEmail Study Center

Study’s details


Contition

Advanced Stage Solid Tumors

Age

0+

Phase

Phase 1

Participants needed

1

Est. Completion Date

Oct 2023

Treatment type

Interventional


Sponsor

Merck KGaA, Darmstadt, Germany

ClinicalTrials.gov identifier

NCT03309150

Study number

MS201923-0007

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.